Phase II trial investigates allogeneic CAR-T for large B-cell lymphoma
Drug Discovery World
JUNE 21, 2024
Allogene Therapeutics and Foresight Diagnostics have announced the initiation of a Phase II trial evaluating the use of cemacabtagene ansegedleucel (cema-cel) as part of the first line treatment regimen for newly diagnosed large B-cell lymphoma (LBCL) patients who are likely to relapse.
Let's personalize your content